Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 12, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3919

Shown on this page

Current sort

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 961–972 of 3,919 matching trials for Prostate Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions: AB001; Drug
Lead sponsor: ARTBIO Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Omaha, Nebraska • Princeton, New Jersey

Conditions: Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: SYS6043; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more

Conditions: Prostate Cancer
Interventions: custom device to demonstrate a significant difference in electrical impedance signatures; Device
Lead sponsor: Ryan J. Halter; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Advanced Solid Tumor
Interventions: DB-1310, Trastuzumab, Osimertinib, capecitabine; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more

Conditions: Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 85 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
Interventions: Nivolumab, Ipilimumab, Carboplatin, Cabazitaxel; Drug
Lead sponsor: Andrew J. Armstrong, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: New York, New York • Durham, North Carolina • Houston, Texas

Conditions: Solid Tumor
Interventions: CPO-100; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Las Vegas, Nevada + 5 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: FPI-2265; Drug
Lead sponsor: Fusion Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • Houston, Texas

Conditions: Prostate Cancer
Interventions: IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose, Dexamethasone, Tamsulosin; Radiation · Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 50 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma, Renal Cell Cancer Metastatic
Interventions: ZM008; Biological
Lead sponsor: Zumutor Biologics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas

Conditions: Prostate Cancer Aggressiveness
Interventions: Subtraction Normalized Expression of Phagocytes Blood Test; Diagnostic Test
Lead sponsor: Immunis.AI; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Sunphenon, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Westwood, Kansas

About this Prostate Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Prostate Cancer clinical trials

How Prostate Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

About this Prostate Cancer clinical trials directory page